Skip to site menu Skip to page content

Adare Pharma Solutions

Better Formulations. Better Outcomes.

Globally integrated CDMO supporting product development through manufacturing and packaging

Subscribed

You have successfully submitted your enquiry. Someone from our company will respond ASAP

About Us

Company social media

Adare Pharma Solutions is a global technology-driven contract development and manufacturing organization (CDMO) providing end-to-end integrated services, from product development through commercial manufacturing and packaging, with small-molecule expertise focusing on oral dosage forms for the pharmaceutical industry.

Adare’s specialized technology platforms provide taste masking, customized release, multiparticulate systems, and patient-centric dosing solutions. With a proven history in drug delivery, Adare’s facilities in the US and Europe have developed and manufactured more than 65 products sold by customers worldwide.

Integrated CDMO services for every step of the process

Adare Pharma Solutions provides comprehensive CDMO services, from the earliest stages of development to commercial manufacturing and packaging for both new and existing products, with expertise in complex formulations and patient-centric technologies.

Patient-centric technology platforms

Adare’s industry-leading experts possess unparalleled experience in the development of unique dosage forms that provide taste masking, customized release, and patient-centric solutions. Our technology platforms overcome complex formulation challenges to improve the lives of all patients, with expertise in pediatric, geriatric, and dysphagic requirements.

Advanced drug delivery technologies that enhance formulation performance, support patient adherence, and deliver customized release for better treatment experiences.
Located in Pessano, Italy, Adare's development and manufacturing facility delivers specialized pharmaceutical expertise, supporting innovative oral drug products from formulation development through clinical supply production.
Adare's Dungan facility in Philadelphia combines advanced packaging, warehousing, and distribution capabilities with controlled-temperature storage, scalable capacity, and infrastructure designed to support pharmaceutical growth.
Adare’s manufacturing expertise enables efficient, flexible, and reliable pharmaceutical production with advanced technologies and capabilities supporting complex formulations and global supply needs.
Adare's oral solid dosage expertise combines specialized formulation, advanced drug delivery technologies, and scalable manufacturing capabilities to help transform complex molecules into differentiated, patient-centric products.
Offering a full range of solid-dose commercial contract packaging services from packaging facilities in the US and Europe.
From concept to commercialization, Adare delivers the capacity, flexibility, and expertise needed for commercial manufacturing success, helping pharmaceutical companies navigate complexity, accelerate timelines, and bring products to market.
Reliable pharmaceutical packaging solutions with bottle filling, blister packaging, serialization, and high-speed cartoning for efficient, compliant production.
Experts in innovative oral dose delivery, specializing in taste masking and customized release technologies to enhance patient experience across diverse populations.
Transforming pharmaceutical possibilities with 3D screen printing technology, enabling customized medicines, multi-drug formulations, tailored release profiles, and enhanced dose flexibility to support the next generation of patient-centric therapies.

A diverse network of facilities offering a full range of CDMO services​

Adare operates facilities in the US and Europe, staffed by over 750 employees.

With a global manufacturing network, Adare offers integrated global and regional supply chains from state-of-the-art facilities in the US and Europe. We deliver development-scale through commercial-scale production, with a continuum of highly specialized manufacturing services and capabilities to meet any customer’s oral solid dose needs.

Adare Pharma Solutions capabilities for seamless scale

Technology platform

  • Solutions to overcome formulation challenges
  • Taste masking
  • Customized drug release
  • Solubility enhancement
  • ODTs and novel dosage forms
  • Easily swallowed dosage forms for patients with difficulty swallowing
  • Optimize efficacy, safety, and dosing frequency
  • Increase therapeutic performance and patient acceptability
  • Maximize dosing accuracy, flexibility, convenience

Development

  • Preformulation
  • Formulation development of
    • Solid dose tablets
    • Capsules
  • Pediatric formulation
  • Product design
  • Formulation optimization
  • 3D screen printing capabilities
  • Sourcing of APIs & excipients
  • Analytical method development & validation
  • Prototype development
  • Small-scale non-GMP & GMP development capabilities

Manufacturing

  • Clinical & commercial manufacturing
  • Global network of facilities
  • Integrated regional supply chains
  • Seamless scale-up & tech transfer
  • Tableting & capsule filling
  • Minitabsâ„¢
  • Granulation and mixing
  • Fluid bed processing
  • Pan coating
  • Blending (Bin and Static)
  • Bilayer tablets
  • Oven drying

Packaging

  • Clinical & commercial contract packaging
  • Packaging facilities in the US and EU
  • Bottle filling
  • Blister packaging
  • Stick pack filling
    • Powders
  • Flow wrap packaging
  • Repackaging license
  • Cartoning
  • DEA Schedules II, 2N, III, 3N, IV, L1
  • Serialization & aggregation

White Papers

Projects

Press Releases

Forest Laboratories to Acquire Aptalis

Aptalis has signed a definitive agreement to be acquired by Forest Laboratories, a leading, fully integrated, specialty pharmaceutical company, for $2.9bn in cash pending required reviews.

Aptalis Pharmaceutical Technologies Expands Licensing Team

Aptalis Pharmaceutical Technologies, a business unit of Aptalis Pharma that develops differentiated products utilizing its oral delivery technologies, today announces that Nigel Ray has been named as the company's Vice President of Global Licensing.

Aptalis Announces European Commission Approval for New Formulation of Viread®

Aptalis Pharmaceutical Technologies, formerly Eurand Pharmaceutical Technologies, focused on developing differentiated oral products utilising its pharmaceutical technologies, today announced that the European Commission has granted marketing authorisation for a new pediatric indication of a new oral granule formulation of Gilead Sciences's Viread® (tenofovir disoproxil fumarate) for HIV-1 infected children aged two to six years of age, and for HIV-1 infected children above six years of age for whom a solid dosage form is not appropriate.

PharmaTelevision Interview to Spotlight Aptalis Pharma’s Year in Review

FDA approvals, revenue gain and organic business growth are just a few of the topics that Aptalis Pharma president John Fraher addresses during an on-air interview with PharmaVentures and PharmaTelevision CEO Fintan Walton. The interview, conducted during BIO 2012 in Boston, reflects Fraher's commentary regarding the integration of companies post Axcan Intermediate Holdings' acquisition of Eurand NV in 2011.

Aptalis Wins Appeal Against Generic Version of AMRIX

Aptalis (previously known as Eurand, Inc.), Cephalon, a wholly-owned subsidiary of Teva Pharmaceuticals Industries Ltd, and Anesta AG prevailed in their appeal to the U.S. Court of Appeals for the Federal Circuit, which reversed a lower court's determination and held that two patents covering the AMRIX muscle relaxant (Cyclobenzaprine Hydrochloride Extended-Release Capsules) are valid.

Eurand to Discuss Strategic Decision-Making at BioEurope Spring

Steve Ellul, Eurand's director of licensing, will discuss aspects of the company's growth strategy during the session 'Understanding the Drivers for Strategic Decision-Making' at BioEurope Spring in Milan, Italy, on Monday 14 March from 9am to 10.30am local time. The panel of industry

Eurand Enters Agreement With Nycomed for ZENPEP in Russia-CIS

Eurand, a global specialty pharmaceutical company, and Nycomed, a privately owned global pharmaceutical company, have announced an exclusive commercialization, license and supply agreement for Russia and the Commonwealth of Independent States (CIS), as well as Georgia and Mongolia. Financial term

Eurand Presents Taste-Masking Technology Webinar

Eurand, a global specialty pharmaceutical company, has conducted a webinar titled 'The $10 Billion Gap: Leveraging Taste-Masking Technologies to Meet Global Patient Needs', presented by Troy Harmon, vice president of business development, and Andrew Thompson, vice president of commercial operatio

Contact Details

Email Address

Address

7722 Dungan Road,
Philadelphia,
PA 19111,
Pennsylvania,
United States of America

Address

Via Martin Luther King, 13,
20060, Pessano con Bornago,
Milan,
Bologna,
Italy

Regional Offices

Address

Adare Pharmaceuticals
7722 Dungan Road
Philadelphia
PA 19111
Pennsylvania
United States of America

Website

Email address

Phone

Address

Adare Pharmaceuticals
Via Martin Luther King, 13
20060, Pessano con Bornago
Milan
Bologna
Italy

Address

Adare Pharmaceuticals
845 Center Drive
Vandalia
45377
Ohio
United States of America

Related Content